Efficacy and safety of oral retinoids in psoriasis

Bibliographys

• LOWE NL, LAZARUS V, MATT L: Systemic retinoid therapy for psoriasis. J. Am. Acad. Dermatol. (1988) 19:186–191.
   PubMed Web of Science ®Google Scholar
• STERN RS, FITZGERALD E, ELLIS C et al.: The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J. Am. Acad. Dermatol. (1995) 33:44–52.
   PubMed Web of Science ®Google Scholar
• •Review of side effects of long-term etretinate use.
   Google Scholar
• SAURAT JH: Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment. J. Am. Acad. Dermatol. (1999) 41(3):52–56.
   Google Scholar
• ••Overview of future directions of retinoidsin psoriasis.
   Google Scholar
• KATZ HI, WAALEN J, LEACH EE: Acitretin in psoriasis: an overview of adverse effects. J. Am. Acad. Dermatol. (1999) 41(3):57–512.
   Google Scholar
• CHANDRARATANA RA: Future trends: a new generation of retinoids. J. Am. Acad. Dermatol. (1998) 39(4):5149–5152.
   Google Scholar
• SINGH BA, WEINBERG JM: Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis. J. Drugs Dermatol. (2004) 3(2):141–143.
   PubMedGoogle Scholar
• WEINSTEIN GD, KOO JY, KRUEGER GG et al.: Tazorotene cream clinical study group. Tazorotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J. Am. Acad. Dermatol. (2003) 48:760–767.
   Google Scholar
• SOFEN H, MOY R, LOWE NJ: Isotretinoin treatment of generalized pustular psoriasis. Lancet (1984) 1:40
   PubMed Web of Science ®Google Scholar
• MOY R, KINGSTON T, LOWE NJ: Isotretinoin versus etretinate therapy in generalized pustular and chronic psoriasis. Arch. Dermatol. (1985) 121:1297–1301.
   PubMed Web of Science ®Google Scholar
• HONNIGSMANN H, WOLFF K: Isotretinoin-PUVA for psoriasis. Lancet (1983) 1:236.
   Web of Science ®Google Scholar
• ANSTEY A, HAWK JL: Isotretinoin-PUVA in women with psoriasis. Br. J. Dermatol. (1997) 136:798–799.
   PubMed Web of Science ®Google Scholar
• ROENIGK RK, GIBSTINE C: Oral isotretinoin followed by psoralens and ultraviolet A or ultraviolet B for psoriasis. J. Am. Acad. Dermatol. (1985) 13(1):153–155.
   PubMed Web of Science ®Google Scholar
• BJERKE JR, GEIGER JM: Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients. Acta Derm. VeneroL Suppl. (1989) 146:206–207.
   PubMedGoogle Scholar
• GOLLNICK H, BAUER R, BRINDLEY C et al.: Acitretin versus etretinate in psoriasis: clinical and pharmacokinetic results of a German multicenter study. J. Am. Acad. Dermatol. (1988) 19(3):458–469.
   PubMed Web of Science ®Google Scholar
• LASSUS A, GEIGER J-M: Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double blind comparison trial. Br. J. Dermatol. (1988) 119:755–759.
   PubMed Web of Science ®Google Scholar
• LASSUS A. GEIGER JM, NYBLOM M, VIRRANKOSKI T, KAARTAMAA M, INGERVO L: Treatment of severe psoriasis with etretin (RO 10-1670). Br. J. Dermatol. (1987) 117:333–341
   PubMed Web of Science ®Google Scholar
• GOLDFARB MT, ELLIS CN, GUPTA AK, TINCOFF T, HAMILTON TA, VOORHEES JJ: Acitretin improves psoriasis in a dose-dependent fashion. J. Am. Acad. Dermatol. (1988) 4(1):655–662.
   Google Scholar
• MURRAY HE, ANHALT AW,LESSARD R et al.: A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J. Am. Acad. Dermatol. (1991) 24(4):598–602.
   Google Scholar
• OLSEN EA, WENDELL WW, MEYER CJ, COBO LM: A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J. Am. Acad. Dermatol. (1989) 21(4):681–686.
   PubMed Web of Science ®Google Scholar
• LING M: Acitretin: optimal dosing strategies. J. Am. Acad. Dermatol. (1999) 43(2):513–517.
   Google Scholar
• BERBIS P, GEIGER JM, VAISSE C, ROGNING C, PRI VAT Y: Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica (1989) 178:88–92.
   PubMedGoogle Scholar
• LEBWOHL M, DRAKE L, MENTER A et al.: Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J. Am. Acad. Dermatol. (2001) 45(4):544–553.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M: Acitretin in combination with UVB or PUVA. J. Am. Acad. Dermatol. (1999) 41(3):522–524.
   Google Scholar
• ••Evaluation of acitretin used in combination with ultraviolet therapy.
   Google Scholar
• RUZICKA T, SOMMERBURG C, BRAUN-FALCO 0 et al.: Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis.Arch. Dermatol. (1990) 126:482–487.
   Google Scholar
• LOWE NJ, PRYTOWSKY JH, BOURGET T, EDELSTEIN J, NYCHAY S, ARMSTRONG R: Acitretin plus UVB therapy for psoriasis. J. Am. Acad. Dermatol. (1992) 24(4):591–594.
   Web of Science ®Google Scholar
• JEST J, BOER J: Combined treatment ofpsoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br. J. Dermatol. (1989) 120:665–670.
   PubMed Web of Science ®Google Scholar
• CARRASCO DA, LEBWOHL M, ROSENBLIT M, SPULS PH: Retrospective study of the efficacy of narrowband UVB and acitretin for the treatment of psoriasis. Proc. Am. Acad. Dermatol. (2004) P689.
   Google Scholar
• TANEW A, GUGGENBICHLER A, HONIGSMAN H, GEIGER JM, FRITSCH P: Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study./ Am. Acad. Dermatol. (1991) 25(4):682–684.
   Google Scholar
• SAURAT J-H, GEIGER J-M, AMBLARD P et al.:Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA, and placebo-PUVA in the treatment of severe psoriasis. Dermatologica (1988) 177:218–224.
   PubMedGoogle Scholar
• MUNCHENBERGER S, SCHOPF E, SIMON JC: The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br. J. Dermatol. (1997) 137:587–589.
   PubMed Web of Science ®Google Scholar
• LAUHARANTA J, GEIGER J-M: A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br. J. Dermatol. (1989) 121:107–112.
   PubMed Web of Science ®Google Scholar
• CARLIN CS, CALLIS KP, KRUEGER GG: Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch. Dermatol. (2003) 139:436–442.
   PubMed Web of Science ®Google Scholar
• ROEGNIK HH: Acitretin combination therapy. J. Am. Acad. Dermatol. (1999) 41(3):518–521.
   Google Scholar
• ROSENBAUM MM, ROEGNIK HH: Treatment of generalized pustular psoriasis with etretinate and methotrexate. J. Am. Acad. Dermatol. (1984) 2:357–361.
   Google Scholar
• VANDERVEEN EE, ELLIS CN, CAMPBELL JP, CASE PC, VOERHEES JJ: Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch. Dermatol. (1982) 118:660–662.
   PubMed Web of Science ®Google Scholar
• BECK HI, FOGED EK: Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatologica (1983) 167(2):94–96.
   PubMedGoogle Scholar
• LARSEN FG, NIELSEN-KUDSK F, JAKOBSEN P, SCHRODER H, KRAGBALLE K: Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J. Clin. Pharmacol. (1990) 9:802–807.
   Google Scholar
• KOO J: Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J. Am. Acad. Dermatol. (1999) 41(3):525–528.
   Google Scholar
• •Current approaches to treating psoriasis in combination and sequential therapy.
   Google Scholar
• KUIJPERS AL, VAN DOOREN-GREEBE JV, VAN DE KERKHOF PC: Failure of combination therapy with acitretin and cyclosporine A in 3 patients with erythrodermic psoriasis. Dermatology (1997) 194:88–89.
   PubMed Web of Science ®Google Scholar
• SAOLOMON D, MESHETT J, MASGRAU-PEYA E, FELDMANN R, SAURAT J-H: Acitretin does not prevent psoriasis relapse related to cyclosporine A tapering. Br. J. Dermatol. (1994) 130:257–257.
   PubMed Web of Science ®Google Scholar
• RIM JH, PARK JY, CHOE YB, YOUN JI:The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy. Am. J. an. Dermatol. (2003) 4(7):507–510.
   PubMed Web of Science ®Google Scholar
• ASHCROFT DM, PO AL, WILLIAMS HC et aL: Combination regimens of topical calcipotriene in chronic plaque psoriasis. Arch. Dermatol. (2000) 136:1536–1543.
   PubMed Web of Science ®Google Scholar
• VAN DE KERKHOF PC, CAMBAZARD F, HUTCHINSON PE et aL: The effect of addition of calcipotriol ointment (5Oug/g) to acitretin therapy in psoriasis. Br. J. Dermatol. (1998) 138:84–89.
   PubMed Web of Science ®Google Scholar
• KOO JY, LOWE N, SEFTON J, WALKER PS: Duration of clinical improvement with oral tazarotene in plaque psoriasis. Proc. Am. Acad. Dermatol. (2004) P598.
   Google Scholar
• •Abstract on the use of oral tazarotene in the treatment of psoriasis.
   Google Scholar
• TANGHETTI EA, POULIN Y, WALKER PS: Oral tazarotene improves scalp psoriasis. Proc. Am. Acad. Dermatol. (2004) P607.
   Google Scholar
• KWANG S, MENTER A, WALKER PS: Oral tazarotene and difficult to treat psoriatic lesions. Proc. Am. Acad. Dermatol. (2004) P597.
   Google Scholar
• BUCCHERI L, KATCHEN B, LARTER AJ, COHEN AR: Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch. Dermatol. (1997) 133:711–715.
   PubMed Web of Science ®Google Scholar
• BRECHER AR, ORLOW SJ: Oral retinoid therapy for dermatologic conditions in children and adolescents. J. Am. Acad. Dermatol. (2003) 49(2):171–182.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of retinoids in thetreatment of paediatric patients.
   Google Scholar
• SHELNITZ LS, ESTERLY NB, HONIG PJ: Etretinate for generalized pustular psoriasis in children. Arch. Dermatol. (1987)123:230–233.
   PubMed Web of Science ®Google Scholar
• ROSINSKA D, WOLFSKA H, JABLONSKA S, KONCA I: Etretinate in severe psoriasis of children. Ped. Dermatol. (1988) 5(4):266–272.
   PubMed Web of Science ®Google Scholar
• Package insert. Roche Laboratories, 2003.
   Google Scholar
• MCELWEE NE, SCHUMACHER MC, JOHNSON SC et aL: An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch. Dermatol. (1991) 127:341–346.
   PubMed Web of Science ®Google Scholar
• SILVERMAN AK, ELLIS CN, VORHEES JJ: Hypervitaminosis A syndrome: a paradigm of retinoid side effects. J. Am. Acad. Dermatol. (1987) 16:267–291.
   PubMedGoogle Scholar
• KATZ HI, WAALEN J, LEACH EE: Acitretin in psoriasis: An overview of adverse effects. J. Am. Acad. Dermatol. (1999) 41(3):57–512.
   Google Scholar
• BOWMAN PH, HOGAN DJ: Ulcerated atrophic striae from etretinate. Cutts (2000) 65(5):327–328.
   PubMed Web of Science ®Google Scholar
• ELLIS CN, KRACH KJ: Uses and complications of isotretinoin therapy. J. Am. Acad. Dermatol. (2001) 45(5):5150–5157.
   Google Scholar
• •Review of complications of isotretinoin.
   Google Scholar
• LEBOWITZ MA, BERSON DS: Ocular effects of oral retinoids. J. Am. Acad. Dermatol. (1988) 19(2):209–211.
   PubMedGoogle Scholar
• BONNETBLANC JM, HUGON J, DUMAS M: Intracranial hypertension with etretinate. Lancet (1983) 2:974.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FT, LABRAICO JM, MEYER SM: Adverse ocular reactions possible associated with isotretinoin. Am. J. OphthalmoL (1985) 100:534–537.
   PubMed Web of Science ®Google Scholar
• HERMAN DC, DYER JA: Anterior subscapsular cataracts as a possible adverse ocular reaction to isotretinoin. Am. J. OphthalmoL (1987) 103:236–237
   PubMed Web of Science ®Google Scholar
• STERN RS, FITZGERALD E, ELLIS CN, LOWE N, GOLDFARB MT, BAUGHMAN RD: The safety of etretinate as long-term therapy for psoriasis: Results of the etretinate follow-up study. J. Am. Acad. Dermatol. (1995) 35:44–52.
   Google Scholar
• WEBER U, MELNIK B, GOERZ G, MICHAELIS L: Abnormal retinal function associated with long-term etretinate. Lancet (1988) 1:235–236.
   PubMed Web of Science ®Google Scholar
• SHALITA k Lipid and teratogenic effectsof retinoids. J. Am. Acad. Dermatol. (1988) 19:197–198.
   PubMed Web of Science ®Google Scholar
• ROSA FW, WILK AL, KELSEY FO: Teratogen update: vitamin A congeners. Teratology (1986) 33:355–364.
   PubMedGoogle Scholar
• PECK GL, DIGIOVANNA JJ: The retinoids. In: Dermatology in general medicine. Freedberg IM, Eisen AZ et al. (Eds), McGraw-Hill, New York (1999):2810–2820.
   Google Scholar
• Package insert, soriatane. Connetics Laboratories, 2004.
   Google Scholar
• PETERSON L: FDA's dermatologic and ophthalmic drugs advisory committee meeting on Allergan's Tazoral for moderate-to-severe psoriasis, Gaithersburg, Maryland July 12, 2004. Trends in Medicine (2004) www.trends-in-medicine.com.
   Google Scholar
• ROLLMAN PIHL-LUBDIN I: Acitretin excretion into human breast milk. Acta Derm. Venereol. (1990) 70:487–90.
   PubMed Web of Science ®Google Scholar
• GRONHOJ LARSEN F, STEINKJER B, JAKOBSEN P et aL: Acitretin is converted to etretinate only during concomitant alcohol intake. Br. J. Dermatol. (2000) 143:1164–1169.
   PubMed Web of Science ®Google Scholar
• MATER H, HONIGSMANN H: Assessment of acitretin-treated female patients of childbearing age and subsequent risk of teratogenicity. Br. J. Dermatol. (2001) 145:1028–1029.
   PubMed Web of Science ®Google Scholar
• MATER H, HONIGSMANN H: Concentration of etretinate is plasma and subcutaneous fat after long-term acitretin. Lancet (1996) 348(9034):1107.
   Web of Science ®Google Scholar
• LARSEN FG, JAKOBSEN P, KNUDSEN J, WEISMANN K, KRAGBALLE K, NIELSEN-KUDSK F: Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J. Invest. Dermatol (1993):623–627.
   PubMed Web of Science ®Google Scholar
• SINGH F, WEINBERG JM: Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis. J. Drugs Dermatol. (2004) 3(2):141–143.
   PubMedGoogle Scholar
• DIGIOVANNA JJ: Isotretinoin effects on bone. J. Am. Acad. Dermatol (2001) 45(5):5176–5182.
   Google Scholar
• KILCOYNE RF: Effects of retinoids in bone. J. Am. Acad. Dermatol (1988) 19(1):212–216.
   PubMed Web of Science ®Google Scholar
• DIGIOVANNA JJ, SOLLITTO RB, ABANGAN DL, STEINBERG SM, REYNOLDS JC: Osteoporosis is a toxic effect of long-term etretinate therapy. Arch. Dermatol (1995) 131(11):1263–1266.
   PubMed Web of Science ®Google Scholar
• GOLLNICK HP: Oral retinoids: efficacy and toxicity in psoriasis. Br. J. Dermatol (1996) 135:S6–S17.
   Google Scholar
• VAN DOOREN-GREEBE RJ, LEMMENS JA, DE BOO T, HANGX NM, KUIJPERS AL,VAN DE KERKHOF PC:Prolonged treatment with oral retinoids in adults: no influence on the frequency of spinal abnormalities. Br. Dermatol (1996) 135\(Suppl. 49):6–17.
   Google Scholar
• MORK NJ, KOLBENSTVEDT A. AUSTAD J: Efficacy and skeletal side effects of two years' acitretin treatment. Acta Derm. Venereol (1992) 72:445–448.
   PubMed Web of Science ®Google Scholar
• LEE AG: Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutts (1995) 5:165–168.
   Google Scholar
• ROENIGK HH: Liver toxicity of retinoid therapy. J. Am. Acad. Dermatol (1988) 19(1):199–208.
   PubMed Web of Science ®Google Scholar
• ROENIGK HH, CALLEN JP,GUZZO CA et al.: Effects of acitretin on the liver. J. Am. Acad. Dermatol. (1999) 41(4):584–588.
   Google Scholar
• KREISS C, AMIN S, NALESNIK MA, CHOPRA K, SHAKIL AO: Severe cholestatic hepatitis in a patient taking acitretin. Am. J. Gastroenterol (2002):775–776.
   PubMed Web of Science ®Google Scholar
• GOLD MH, ROENIGK HH, VANAGUNAS A: The retinoids and inflammatory bowel disease. Arch. Dermatol (1988) 124(3):325–326.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, GOLDFARB MT, ELLIS CN, VOORHESS JJ: Side effect profile of acitretin in psoriasis. J. Am. Acad. Dermatol (1989) 20(6):1088–1093.
   PubMed Web of Science ®Google Scholar
• VAHLQUIST C, SELINUS I, VESSBY B: Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. Acta Derm. Venereol (1988) 68(4):300–305.
   PubMed Web of Science ®Google Scholar
• ZELICKSON BD, MULLER SA: Generalized pustular psoriasis: a review of 63 cases. Arch. Dermatol. (1991) 127(9):1339–1345.
   PubMed Web of Science ®Google Scholar
• http://www.shareholder.com/agn/ Release Detail Allergan, press release. September 27, 2004.
   Google Scholar